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Abstract. The aim of the present prospective-retrospective 
study was to evaluate the response of high-risk canine mast 
cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) 
and to correlate this with prognostic factors. A total of 
24 dogs presented with macroscopic cutaneous MCTs at 
disease stage II or III, and therefore, at high-risk of associ-
ated mortality, were included in the study and treated with 
masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs 
achieved an objective response and the overall survival (OS) 
for all subjects was 113 days. Dogs responding to treatment 
had a significant increase in OS compared to non‑responders 
(146.5 days vs. 47 days, P=0.02). Internal tandem duplications 
in exon 11 of the c‑kit gene were identified in 6/24 cases. Ki67, 
KIT immunolabelling and c-kit mutation did not provide 
information regarding prognosis or prediction of response to 
TKIs in this population. Initial response to TKIs appears to be 
the most reliable prognostic factor for survival duration.
Introduction
Mast cell tumour (MCT) is the most common cutaneous 
malignancy in dogs (1). In view of the wide variation in its 
biological behaviour, many prognostic factors have been 
proposed and evaluated in an attempt to improve decision 
making in the management of this neoplasm (2-4). Among 
the therapeutic approaches, surgery stands out as the optimal 
treatment offering the highest rate of cure for most low to 
intermediate grade MCTs (1,3,5). However, for high grade or 
biologically aggressive tumours, surgical benefit is limited and 
metastasis may occur in up to 90% of cases (2,3). Numerous 
drugs, including glucocorticoids, chemotherapeutic agents and 
tyrosine kinase inhibitors (TKIs) have been used for treatment 
of non-resectable MCTs, but the prognosis for such tumours 
remains guarded to poor (1,3,4). Tyrosine kinases (TKs) are 
enzymes located on the cell surface, cytoplasm or nucleus, 
that catalyze the transfer of phosphate groups from adenosine 
triphosphate molecules (ATP), leading to cellular signaling 
transmission. In cancer cells, several abnormalities may be 
found in specific protein kinases, which allows transduction 
of intracellular signals that ultimately will cause changes in 
gene transcription, increase cell proliferation, invasion and 
survival (6,7). Genetic and epigenetic changes can result in 
alteration in oncogenes or tumour suppressor genes expression 
leading to constitutively activated TKs , or abnormal TKs 
interactions (7-9).
Several molecular abnormalities have been identified and 
characterized in Veterinary Medicine, particularly in canine 
MCTs (10). Gain of-function mutations involving the KIT 
receptor and its pathway are considered relevant for the prog-
nosis and treatment of MCT (11-14).
Dysregulation of several TKs have been found in different 
human cancers. Monoclonal antibodies like trastuzumab and 
cetuximab that respectively target HER-2 and EGFR TK 
receptors have been approved for human breast cancer (7,15). 
Imatinib mesylate is a small molecule TKI with a multi-target 
action towards KITr, PDGFR and Bcr-Abl protein. Imatinib 
is a well recognized and effective treatment for human 
gastro-intestinal stromal tumours and chronic myeloid 
leukemia (16). In veterinary medicine, imatinib was occasion-
ally used in the treatment of canine MCT (17), and greatest 
effort was directed to the development ofsimilar TKI for 
veterinary use (7,10).
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Masitinib mesylate and toceranib phosphate, are TKIs 
licensed for use in dogs with non-resectable Grade II or 
III MCTS in Europe and the United States. They both act 
intracellularly in the protein kinases KITR and PDGFR α/β, 
where masitinib also operates in Lyn, Fyn and Lck (18), and 
toceranib in VGFR and Flt-3 (19). The action against multiple 
therapeutic targets, allows these molecules to interfere more 
effectively in the different pathways responsible for cancer 
progression (7). However, despite the development of such 
drugs and their increasing use in clinical practice, there is still 
a lack of established factors that can predict the response to 
treatment of canine MCTs toTKIs (4,10).
The objective of this study was to evaluate measurable 
responses of canine MCT to TKIs, correlating this with 
clinical, histopathological, imunohistochemical and genetic 
prognostic factors.
Materials and methods
Subject selection and treatment. This study included subjects 
retrospectively collected from the Queen's Veterinary School 
Hospital (QVSH) at the University of Cambridge (Cambridge, 
UK) (n=10), and prospectively enrolled from the Veterinary 
Hospital of the Universidade Federal de Minas Gerais (UFMG, 
Belo Horizonte, MG, Brazil)(n=14). The dogs were enrolled if 
presented with macroscopic cutaneous MCT and stage II, III 
or IV disease, considered to be at high-risk of MCT related 
death. For classification as a high‑risk stage II, only a cyto-
logical diagnosis of certain metastasis, was accepted (20).
Incisional biopsies of primary tumours were performed 
and subjected to histological (Patnaik and Kiupel grading 
systems), immunohistochemical (Ki-67 and KITr) and genetic 
(c‑kit oncogene) assessment. Clinical staging was performed 
by physical examination, abdominal ultrasound, fine needle 
aspiration and cytology of regional lymph nodes, satellite or 
distant skin lesion and suspected visceral lesions. Lymph node 
metastasis were identified, on fine needle aspirates (FNA) 
using cytological criteria previous published (20).
Dogs were treated with masitinib, at a dosage ranging from 
8 to 12.5 mg/kg q 24 h or toceranib at a dosage of 2.5-2.7 mg/kg 
q 48 h. The concomitant use of prednisone or prednisolone, at 
an initial dosage of 40 mg/m2, daily, (7-10 days), followed by a 
dosage of 25 mg/m2, daily or every other day was often used, 
along with gastric acid inhibitors (omeprazole, ranitidine), for 
controlling paraneoplastic effects related to degranulation of 
mast cells.
Follow up information was collected from the subjects 
medical records or when necessary by telephone call conver-
sation with the referring veterinary surgeon or the owner. 
Subjects which failed to comply with TKIs treatment or 
attendance during the clinical follow-up were excluded from 
this study.
This study was approved by the Ethics Committee on 
Animal Use (UFMG, protocol 384/2013) and Department's 
Ethics and Welfare Committee (University of Cambridge, 
protocol CR 138).
Histological analysis. The surgical specimens of the primary 
tumours were fixed in 10% formalin, cut in longitudinal 
sections for paraffin embedding, and 4 µm sections were 
mounted in glass and stained with hematoxylin-eosin 
and toluidine blue. Histopahological examination was 
performed by FC and RH, and tumour grading was defined 
through the systems proposed by Patnaik et al (21) and 
Kiupel et al (22).
Immunohistochemical analysis. Sections of 4 µm were cut 
from a representative block for each case and collected on 
gelatin-coated slides. The slides were deparaffinized and 
rehydrated in an alcohol series. Antigenal retrieval was 
performed with an antigen retrieval solution (Target Retrieval 
Solution Citrate pH 6, DakoCytomation, Glostrup, Denmark) 
under pressurized heat (20‑25 mmHg, 125˚C/2 min). 
Endogenous peroxidase was blocked by immersion in 3% 
hydrogen peroxide and protein blockage (Thermo Scientific 
UltraVision™ Protein Block; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA). Primary antibodies CD117 (policlonal, 
1:800; DakoCytomation, Glostrup, Denmark) and MIB-1 
(monoclonal, 1:25; DakoCytomation) were incubated at 4˚C, 
for 16 h (overnight) for KITr and Ki-67 reactions, respectively. 
Secondary antibody (Advance HRP Link; DakoCytomation) 
was incubated in the humidity chamber for 30 min and the 
reaction was amplified by the polymer (Advance HRP Enzyme; 
DakoCytomation). The reaction was revealed with the chro-
mogen 3,3-diaminobenzidinetetrahydrochloride (Liquid 
DAB + SubstratChromogen System; DakoCytomation) and 
stained with Harris hematoxylin.
The immunolabelling pattern for KITr was evaluated, by 
counting membrane, focal or difuse cytoplasmic immunoex-
pression (KIT patterns I, II or III, respectively) in 100 mast 
cells at a x40 magnification. Each MCT was assigned with the 
highest staining pattern present in at least 10% of the neoplastic 
cell population or present in large clusters of neoplastic cells 
within the tumour, as described by Kiupel et al (23). Ki-67 
value was determined as the percentage of positive nuclei in at 
least 500 neoplastic cells in 3‑5 high power fields (x40 magnifi-
cation). Every nucleus with evidence of immune labelling was 
considered positive for Ki-67. This approach was described 
by Scase et al (24). Previously tested canine MCT samples 
were used as positive control for KITr and Ki-67, and negative 
controls were obtained by replacing the primary antibody by 
normal serum.
Screening of mutations in the c‑kit oncogene. The polymerase 
chain reaction (PCR) for amplification of the fragment of 
interest in the c‑kit oncogene, was performed by Progen, in 
Vetpat Laboratory (Campinas, SP, Brazil), from the DNA 
extraction in paraffin embedded tumour, by the proteinase 
K method. The primers used in the bleaching of the reaction 
were designed with the help of the BLAST software (Basic 
Local Alignment Search Tool®, NCBI) and manufactured by 
Invitrogen (São Paulo, SP, Brazil), as c‑kit forward: 5'-ATC 
TGT CTC TCT TTT CTC CCC C-3' (sense) and c‑kit reverse: 
5'-TGG GGT TCC CTA AAG TCA TTG T-3' (antisense). The 
product generated by these pair of primers had 225 bp in the 
absence of mutations (native c‑kit). Reactions were prepared 
and planned in a GenPro thermocycler (BIOER Technology), 
with a maintenance at 95˚C for five min, then 30 cycles of 94˚C 
for 45 sec for denaturation of DNA strands, 63˚C for 45 sec 
to pairing and annealing of primers and 72˚C for one minute 
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to extension, to be finally maintained at 72˚C for ten min for 
molecular stabilization. The amplified material was separated 
by electrophoresis at 100V, with free amperage. Canine 
healthy skin samples and milique water were used as positive 
and negative controls, respectively.
Assessment of response and toxicity. Tumour response to TKI 
was based on measurements of the primary tumour and all 
target lesions (including metastatic lymph nodes) before and 
two-weeks after starting treatment, as recommended by the 
Response Evaluation Criteria for Solid Tumours (RECIST, 
v.1.0) (25). Complete response (CR) was defined as a complete 
disappearance of the mass(es), partial response (PR) was 
defined as at least 30% reduction in size, stable disease 
between 20% reduction and 20% increase in size, progressive 
disease was defined as an increase in size of the mass of more 
than 20%. Overall response rate (ORR) was calculated based 
on the total number of subjects that achieved complete and 
partial response (CR+PR). The disease-free interval (DFI), for 
subjects who achieved complete remission and overall survival 
(OS) for all subjects were calculated from the start of TKI 
administration. Cytology was used to confirm the diagnosis 
in case of progressive disease and appearance of new lesions. 
Side effects related to the use of TKI were recorded according 
to Veterinary Cooperative Oncology Group-Common 
Terminology Criteria for Adverse Events (VCOG-CTCAE 
v.1.1) (26).
Statistical analysis. Statistical analysis was performed using 
GraphPad Prism (v.6.01). A matrix correlation was built 
through Spearmann test for searching association between 
prognostic factors and overall survival. DFI and OS were 
estimated through Kaplan-Meier curve and the log-rank test 
of Cox-Mantel was used to compare the curves, according to 
prognostic factors. P<0.05 was considered to indicate a statis-
tically significant difference. Significant correlations were 
considered strong when they occurred in over than 49% of the 
studied population (r>0.07), moderate, as occurred in 9-49% 
(0.3<r<0.7), and weak, when they occurred in less than 9% of 
the population (r<0.3).
Results
A total of 24 dogs were included in this study (Table I). 
Fourteen cases were enrolled prospectively, from the 
Veterinary Hospital, UFMG and 10 cases were retrospectively 
included, identified from medical records of subjects treated 
at the QVSH, University of Cambridge. Tyrosine kinase 
inhibitors were used as first line therapy in 11 dogs and as a 
rescue treament in 13 dogs. All except one subject received 
concomitant prednisone (n=13, all from UFMG) or pred-
nisolone (n=10, from QVSH). Sixteen subjects had received 
previous chemotherapeutic agents including: lomustine (n=9), 
vinblastine (n=4), lomustine followed by chlorambucil (n=2), 
lomustine followed by vinblastine (n=1). Toceranib was used 
instead of masitinib in four subjects.
An objective response was obtained in 12/24 subjects 
(50%), seven of which had CR (29%) and five PR (21%) as 
shown in Figs. 1 and 2, respectively. Stable (n=4; 17%) or 
progressive disease (n=8; 33%) was observed in 12 subjects 
(50%). One subject developed partial remission with masi-
tinib, as a first line therapy, resulting in the tumour becoming 
resectable. Surgery was performed and the subject continued 
masitinib treatment with a DFI of 86 days, and an OS of 
288 days (144 days after surgery).
The overall survival time for all subjects in this study was 
113 days but DFI and OS for subjects who achieved CR was 140 
and 164 days. In a matrix correlation only the initial response 
to TKIs was associated with OS (P=0,03; rS=0,578). As shown 
in Fig. 3, subjects who achieved measurable responses during 
the first weeks of treatment (n=12) reached the median at 
146 days, while those who remained with stable or progressive 
disease (n=12) reached the median at 47 days (P=0.02).
Eleven subjects were treated with TKIs as a first line 
treatment, but 81.8% (9/11) of these, were treated only after 
post surgical recurrence of the tumour. The ORR for tumours 
treated with TKI as first line treatment was 54.5% (6/11). 
Thirteen dogs received TKIs as a second line treatment and 
69,2% (9/13) of these had previous surgery as well. The ORR 
for tumours treated with TKI as a second line treatment was 
46,2% (6/13). The difference in ORR between the two groups 
of subjects treated with TKIs as a first or second line treatment 
was not statistically significant. There was also no significant 
difference in DFI and OS for the same two groups of subjects, 
however a tendency for significance in OS was found between 
the first line treatment compared to the second line treatment 
group (160 and 103 days, respectively; P=0,2). Similarily, there 
was no difference in ORR between subjects treated on the first 
presentation of MCT or after post surgical recurrence of the 
tumour, however a tendency for significance in OS was found 
between non-recurrent and recurrent MCTs (123 and 66 days, 
respectively; P=0,09).
Clinical staging was also not statistically related to prog-
nosis, and subjects in stage II (n=6) and III (n=17), reached a 
median OS of 130 and 123 days, respectively (P=0,8). There 
was also no influence of histological grade, mitotic index 
(1‑60 mitotic figures in 10 high‑power fields) and Ki‑67 value 
(5,4-46,0%) in OS of these subjects.
Abnormalities in KIT expression were identified in 
17/24 (71%) MCTs, 12 with KIT II-pattern and four with a 
KIT III-pattern, but there was also no correlation with OS. 
Nevertheless, objective responses (CR+PR) were obtained 
in 28% (2/7), 54% (7/13) and 75% (3/4) of subjects whose 
tumours presented with KIT expression pattern I, II and III, 
respectively, although the number was not appropriate for 
a contingency analysis. Duplications in exon 11 of the c‑kit 
gene were identified in 6/24 subjects (24%). Of these, measur-
able responses were observed in 4/6 (67%). A similar rate of 
response was found for subjects without any identified muta-
tions, through the elected method (8/18, 44% of response to 
TKI). There was also no difference in OS, according to the 
mutational status in the exon 11 of the c‑kit oncogene.
Positive correlations were found between mitotic index and 
both grading systems (P=0,009; rS=0,523 for Patnaik grading 
system; P=0,001; rS=0,617 for Kiupel grading system), KITr 
pattern and Patnaik grading system (P<0,00001; rS=0,676) 
and both grading systems (P=0,0006; rS=0,650). Ki67 was not 
correlated with MI or Patnaik and Kiupel grade.
Side effects were relatively common and are reported 
in Table II. One dog developed severe illness after 
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133 days of masitinib. The subject presented with a grade 4 
non-regenerative anaemia with concomitant thrombocyto-
penia, grade 2 azotemia and grade 4 proteinuria resulting 
in hypoalbuminemia/ascites (nephrotic syndrome). The dog 
was treated with total blood transfusion and fluidtherapy and 
the drug was suspended, but despite the subject's recovery, 
tumour recurrence was noted 28 days later and the dog was 
euthanized.
Discussion
In this study, as previously reported by Smrkovski et al (27), 
a 50% ORR was observed in dogs with unresectable MCTs, 
treated with TKIs.
The OS of dogs in this study was lower in comparison to 
reports of Smrkvoski et al (27) and Hahn et al (28). Three 
main hypotheses might explain this difference: Firstly, our 
study included a high number of subjects with post surgical 
recurrent MCTs (18/24) which showed reduced survival rates 
compared to non recurrent MCT, althought this was not statis-
tical significant. A poor outcome is historically reported for 
recurrent MCTs with related death rates reaching 86-100% of 
cases as reported by Patnaik et al (21); Secondly, TKIs were 
administered after failure of chemotherapy in over half of 
these subjects. As shown by Hahn et al (28), better responses 
were obtained when mastinib mesylate was used as a first 
line treatment. However, in our study, no differences were 
seen in OS in subjects treated as a first or second line treat-
ment with TKIs. A third and most likely hypothesis is that 
the concomitant use of glucocorticoids might have impaired 
a favourable and prolonged response to TKIs. The mecha-
nisms involved in tumour resistance to TKIs are still largely 
unknown, but appear to involve abnormalities in genes 
responsible for the synthesis of other areas of the targeted 
proteins, or development of alternative cellular pathways (29). 
Another mechanism of resistance is the overexpression 
of ABC transporters (30). Imatinib and dasitinib are TKIs 
similar to masitinib in its mechanism of action and they are 
substrates of the ABC transporters, such as P-glycoprotein 
(P-gp, ABCB1) and breast cancer resistance protein (BCRP, 
ABCG2), both induced by the administration of glucocor-
ticoids (30). Masitinib is also a P-gp substrate and P-gp 
overexpression can increase the resistance to masitinib (31). 
However, multitarget TKIs similar to toceranib, as sunitinib, 
have been found to inhibit the ABC (32,33). The authors 
and collaborators found a significant increase in survival in 
subjects treated with masitinib alone compared to subjects 
treated with masitinib in combination with prednisolone 
(data still not published). The efficacy of mastinib could 
be reduced by the development of a rapid drug resistance 
caused by the induction of P-gp, from previous or concurrent 
prednisolone treatment, while toceranib could or could not 
be affected. In our study only four subjects were treated with 
toceranib and prednisolone, too few to allow any conclusion. 
Further studies are needed to evaluate the benefit of adding 
corticosteroids to masitinib or toceranib.
In this study, one subject received adjuvant therapy with 
masitinib, once this TKI resulted in partial response of its 
previous unresectable disease, making it resectable. This 
subject reached an OS of 288 days from the beginning of 
neoadjuvant treatment with masitinib, superior to the median 
obtained in this study (113 days). This observation could suggest 
that TKIs responses in the treatment of gross disease may also 
be useful in the adjuvant scenario. In the presence of minimal 
residual disease, a reduced development of tumour resistance 
and even a synergism with other therapeutic approaches could 
be hypothesized. New clinical trials are required to evaluate 
the response of canine MCT to these drugs in the adjuvant 
setting.
In this case series, including dogs with advanced 
staged disease, the initial response to TKIs was the most 
significant prognostic factor, as previously reported by 
Smrkovski et al (27) and Grant et al (34). In contrast, 
histological grade, mitotic index, Ki-67 value, KITr pattern 
and even the mutational status in exon 11 of the c‑kit onco-
gene had no impact on OS for these subjects. Increased 
Figure 1. French Bulldog presenting with (A) a mast cell tumour metastasis 
on cervical superficial lymph node, (B) but with complete remission after 
12 days of treatment with masitinib mesylate.
Table II. Adverse side effects observed in 24 dogs with 
advanced staged mast cell tumours treated with tyrosine kinase 
inhibitors (23 were also treated with glucocorticoids).
Adverse side effect Grade Frequency (%)
Anaemia Grade 2 1/24 (4.2)
 Grade 4 1/24 (4.2)
Thrombocytopenia Grade 4 1/24 (4.2)
Neutropenia Grade 1 16/24 (66.7)
ALP increase Grade 1 12/24 (50)
ALT increase Grade 1 1/24 (4.2)
 Grade 2 2/24 (8.3)
Azotemia Grade 2 1/24 (4.2)
Proteinuria Grade 1 1/24 (4.2)
(increase urine Grade 3 1/24 (4.2)
protein/creatinine Grade 4 1/24 (4.2)
ratio) 
Hypoalbuminaemia Grade 4 1/24 (4.2)
ALP, alkaline phosphatase; ALT, alanine transferase.
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response rate was found in subjects with II and III KITr 
staining patterns and in the presence of ITD in the exon 
11 of c‑kit oncogene, however due to the low number in 
each subcategory the statistical significance could not be 
evaluated. The prognostic value of KITr immunelabelling 
pattern has been evaluated in some studies and although 
Kiupel et al (2004) showed that the KITr immunelabelling 
pattern could be a prognostic factor for canine MCT (23), 
this was not confirmed in more recent studies (35,36). The 
relevance of c‑kit mutational status, as a predictor for TKI 
response was suggested in older studies (17,19,28). We 
found an increase response rate in samples arboring c‑kit 
mutations compared with samples with absent mutations, 
however the number of cases was too small to draw any 
significant conclusion.
The main limitations of this study were the relatively low 
number of samples and the heterogenicity of the subjects 
and type of treatment used, however this is often a common 
problem in studies of canine MCTs. Genetic assessment of 
exon 11 was performed using PCR analysis rather than genetic 
sequencing, so point mutations in the exon 11, could not be 
assessed. Primers applied in this study were limited only to the 
exon 11, but whereas there might be c‑kit activating mutations 
in other loci, like exons 2, 5, 6, 7, 8, 9 and 15, (14), these are 
not proven, at the current state of our knowledge, to be of 
prognostic or predictive significance.
Although the number of cases in this study was small, there 
was no correlation between mitotic index and Ki-67 value, 
which differs from the study conducted by Berlato et al (37). 
However a moderate correlation was found between mitotic 
index and both grading systems, Patnaik's grading system and 
KITr pattern. As expected and previously demonstrated by 
Giantin et al (35), both grading systems were also moderately 
correlated with each other.
Masitinib and toceranib are generally well tolerated in 
dogs, although mild and self-limiting side effects may occur. 
However, clinical-pathological abnormalities should always 
be monitored, once severe side effects may occur, like non 
regenerative anaemia and moderate to severe proteinuria, as 
seen in our study and also by Miller et al (38).
In conclusion, TKIs can be effective in the treatment of 
macroscopic advanced staged canine MCTs. Nevertheless, 
there is lack of factors that could strongly predict the response 
to treatment. Similar to other studies, we found that the initial 
response to treatment is the only reliable prognostic factor for 
those subjects regardless of theclinical stage, histological grade 
and mitotic index. Nevertheless, history of recurrent MCTs 
and previous chemotherapeutic agents may reduce response 
rate. As found in our preliminary results, concomitant use of 
glucocorticoids may impair the response to TKIs and possibly 
induce early TKI resistance resulting in reduced OS. Differently 
to other similar papers published before all samples were evalu-
ated for Ki-67 value, immunohistochemical pattern of KITr 
and even the mutational status in exon 11 of the c‑kit oncogene. 
Ki67, KITr immunostaining and c‑kit mutation did not give any 
further relevant informations regarding prognosis and or in the 
prediction of response to TKIs in the cohort of high-risk MCTs 
examined, although expression of KIT II and III might result in 
higher response rate.
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Figure 2. French Bulldog presenting a cutaneous mast cell tumour in the prepuce region with (A) favorable response to masitinib mesylate, resulting in partial 
remission in (B) 10 days and (C) 30 days. Note the persistence of satellite nodules on the skin near the prepuce (C).
Figure 3. Graphical representation of overall survival for 24 subjects with 
advanced-stage, macroscopic canine mast cell tumour, treated with tyro-
sine kinase inhibitors, in accordance with the initial response to treatment 
(Md=146.5 days for those who presented partial or complete response and 
Md=47 days for those with stable or progressive disease; P=0.02). Graph Pad 
Prism v. 6.01.
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